JOINT FILING AGREEMENTJoint Filing Agreement • May 29th, 2003 • Orbimed Capital LLC • Pharmaceutical preparations
The undersigned hereby agree that the Statement on this Schedule 13G, dated May 28, 2003, (the "Schedule 13G"), with respect to the Common Stock, par value $.001 per share, of Atrix Laboratories, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities and Exchange Act of 1934, as amended, and that this Agreement shall be included as an Exhibit to this Schedule 13G. Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13G, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.
JOINT FILING AGREEMENTJoint Filing Agreement • September 29th, 2003 • Orbimed Capital LLC • Pharmaceutical preparations
The undersigned hereby agree that the Statement on this Schedule 13G/A, dated September 24, 2003, (the "Schedule 13G/A"), with respect to the Common Stock, par value $.01 per share, of ArQule, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities and Exchange Act of 1934, as amended, and that this Agreement shall be included as an Exhibit to this Schedule 13G/A. Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13G/A, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.
JOINT FILING AGREEMENTJoint Filing Agreement • June 29th, 2004 • Orbimed Capital LLC • Pharmaceutical preparations
The undersigned hereby agree that the Statement on this Schedule 13G, dated June 14, 2004 (the "Schedule 13G"), with respect to the Common Stock, par value $0.001 per share, of Atrix Laboratories, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities and Exchange Act of 1934, as amended, and that this Agreement shall be included as an Exhibit to this Schedule 13G. Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13G, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.
JOINT FILING AGREEMENTJoint Filing Agreement • September 3rd, 2004 • Orbimed Capital LLC • Pharmaceutical preparations
The undersigned hereby agree that the Statement on this Schedule 13G, dated August 16, 2004, (the "Schedule 13G"), with respect to the Common Stock, $0.01 par value per share, of Tanox Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities and Exchange Act of 1934, as amended, and that this Agreement shall be included as an Exhibit to this Schedule 13G. Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13G, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.
JOINT FILING AGREEMENTJoint Filing Agreement • December 16th, 2003 • Orbimed Capital LLC • Biological products, (no disgnostic substances)
The undersigned hereby agree that the Statement on this Schedule 13G, dated December 16, 2003, (the "Schedule 13G"), with respect to the Common Stock, par value $.001 per share, of NPS Pharmaceuticals, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities and Exchange Act of 1934, as amended, and that this Agreement shall be included as an Exhibit to this Schedule 13G. Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13G, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.
JOINT FILING AGREEMENTJoint Filing Agreement • September 3rd, 2004 • Orbimed Capital LLC • Biological products, (no disgnostic substances)
The undersigned hereby agree that the Statement on this Schedule 13G, dated August 16, 2004, (the "Schedule 13G"), with respect to the Common Stock, par value $.001 per share, of NPS Pharmaceuticals, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities and Exchange Act of 1934, as amended, and that this Agreement shall be included as an Exhibit to this Schedule 13G. Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13G, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.
